SUBSCRIBE
SUBSCRIBE
News   Business

NeoGenomics, Inc. Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013

July 31, 2013 | 
1 min read

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FT. MYERS, Fla., July 31, 2013 -- /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2013.

Second Quarter 2013 Highlights:

  • Earnings per share of $0.01 per share on net income of $273k

  • Adjusted EBITDA(1) of $1.8 million

    • Hey, check out all the research scientist jobs. Post your resume today!

    Earnings
    MORE ON THIS TOPIC
    cutting off a row of people into pieces
    Layoffs
    Editas Axes 60% of Staff, Sickle Cell Therapy After Failing to Find Partner
    December 13, 2024
     · 
    2 min read
     · 
    Tristan Manalac
    Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
    Layoff Tracker
    Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff
    December 12, 2024
     · 
    205 min read
     · 
    BioSpace Editorial Staff
    Podcast
    Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
    December 11, 2024
     · 
    1 min read
     · 
    Heather McKenzie
    Group Of Employees Being Fired By Their Company.
    Layoffs
    Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
    December 10, 2024
     · 
    2 min read
     · 
    Angela Gabriel